Integral Diagnostics reports $788.7M FY26 revenue

• Integral Diagnostics reported financial results for FY26, featuring a 25.6% increase in revenue to $788.7 million.
• Operating NPAT increased by 50.1% to $47.4 million, while the company declared a fully franked final dividend of 6 cents per share.
• Financial growth was driven by higher revenue and margin expansion, alongside contributions from Capitol Health operations acquired in December 2024.

Integral Diagnostics (ASX:IDX) announced its financial results for the year ended June 30, delivering an operating net profit after tax of $47.4 million, which represents a 50.1% increase compared to the prior period.

Revenue and other income came to $788.7 million, up 25.6%, while operating EBITDA was $164.8 million, up 30.3%.

The result aligns with the preliminary unaudited figures released on Aug. 10 and reflects operational contributions from the acquisition of Capitol Health completed in late 2024.

"The strength of the result was also reflected in operating free cash flow growth of 30.7% and a further reduction in leverage to 2.3x, reinforcing the quality of our earnings, financial discipline and the strength of our balance sheet," stated Jason Martinez, Managing Director and CEO of IDX.

Specific operational metrics showed that operating EBITDA rose 30.3% to $164.8 million, with operating free cash flow reaching $106.4 million.

Statutory NPAT stood at $22 million after accounting for $25.4 million in transaction, integration, restructuring, and share-based expense costs.

Following the announcement, the Integral Diagnostics share price was down at $2.27.

A fully franked final dividend of 6 cents per share has been declared, up 50% from the prior corresponding period. This brings the total FY26 dividend of 9.3 cents per share.

The business reduced its net debt to operating EBITDA leverage ratio from 2.6x down to 2.3x as of June 30.